Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Related Keywords

United States , ,Future Treatment Strategies ,How Do Practice Patterns Compare ,Lower Risk Mds ,Lower Risk Myelodysplastic Syndrome ,Myelodysplastic Syndrome ,Mds ,Erythropoietin ,Hypomethylating Agents ,Growth Factor Support ,Erythropoiesis Stimulating Agents ,Esa ,